Unicycive Therapeutics (UNCY) AI Stock Analysis

• Market Cap: $139.91M
• Dividend Yield: N/A
• Average Volume (3M): 529.47K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.83
• Revenue Growth: N/A
• EPS Growth: 66.05%
• Country: US
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 21,491,396
• 10 Day Avg. Volume: 808,040
• 30 Day Avg. Volume: 529,471
• PEG Ratio: >-0.01
• Price to Book (P/B): 7.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.86
• Enterprise Value/Market Cap: 0.70
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -357.07
• Enterprise Value/Ebitda: -4.71
• 1Y Price Target: $39.50
• Price Target Upside: 470.81% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $6.00 ▼(-13.29% Downside)

The score is primarily constrained by weak financial performance (no revenue, sizable losses, and significant cash burn), only partly offset by a strengthened, low-debt balance sheet. Technical signals are mixed with no clear momentum, and valuation provides limited support due to negative earnings and no dividend.

Positive Factors

Low Leverage / Stronger Equity

Very low leverage and meaningful equity improvement provide lasting financial flexibility to fund clinical development and remediate regulatory issues. A stronger balance sheet reduces short-term solvency risk and supports continued R&D investment without immediate refinancing pressure.

Sufficient Near-Term Cash Runway

A runway into 2027 materially reduces near-term liquidity risk, allowing the company to pursue FDA resubmission and potential launch activities without urgent capital raises. This stability supports execution on regulatory milestones and gives management time to de‑risk OLC development.

Product Differentiation (OLC reduces pill burden)

A therapy that reduces pill burden addresses a durable clinical pain point in dialysis care and can create a sustainable commercial advantage if approved. Improved adherence can translate to stronger formulary positioning and longer-term market share versus existing phosphate binders.

Negative Factors

Pre-Revenue with Sustained Cash Burn

Persistent zero revenue and large negative operating and free cash flow create ongoing financing needs. Over the medium term, continued cash burn can dilute shareholders, constrain R&D choices, and force strategic tradeoffs if clinical or regulatory setbacks delay commercialization.

Manufacturing Compliance Issue Caused CRL

A third‑party manufacturing compliance problem that triggered a CRL is a structural execution risk: remediation can be time-consuming, costly, and may require supply‑chain changes. Such issues can materially delay approval and compress the commercial window upon launch.

Revenue Dependent on Regulatory Approval of OLC

The business model is highly binary: long‑term revenue hinges on one lead candidate achieving regulatory approval and market adoption. This single‑asset dependence increases commercial and regulatory risk, leaving the company vulnerable if OLC fails or faces market access challenges.

Unicycive Therapeutics Business Overview & Revenue Model

Company Description

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

How the Company Makes Money

Unicycive Therapeutics makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model primarily involves conducting research and development to bring its therapeutic products through clinical trials and eventually to market. Key revenue streams include potential sales from its approved drugs, licensing agreements, and partnerships with other pharmaceutical companies. Unicycive may also receive milestone payments and royalties from collaborations or licensing deals that leverage its proprietary technologies and drug candidates.

Unicycive Therapeutics Financial Statement Overview

Summary

Financial profile is weak overall due to zero revenue and large ongoing losses (TTM EBIT -$31.6M; TTM net loss -$33.4M) alongside heavy cash burn (TTM operating cash flow -$29.8M; TTM free cash flow -$29.9M). The key offset is an improved, low-leverage balance sheet (debt-to-equity ~0.01; equity up to $37.5M vs. $7.4M in 2024), but continued burn remains a major risk.

Income Statement

UNCY remains a pre-revenue biotechnology company, with Total Revenue at $0 in TTM (Trailing-Twelve-Months) and 2024, following modest revenue in 2022–2023. Losses are substantial and persistent, with TTM (Trailing-Twelve-Months) EBIT of -$31.6M and Net Income of -$33.4M, broadly in line with 2024’s -$36.7M net loss. While the trajectory shows some improvement versus 2024, the lack of recurring revenue and continued heavy operating losses keep the income statement profile weak.

Balance Sheet

The balance sheet is a relative strength: leverage is very low in TTM (Trailing-Twelve-Months) with Total Debt of $0.27M against Stockholders’ Equity of $37.5M (debt-to-equity ~0.01). Equity and assets have improved meaningfully versus 2024 (equity $7.4M) and contrast with negative equity in 2022–2023, indicating recapitalization and improved financial footing. The key risk remains ongoing losses (TTM return on equity is sharply negative), which can pressure equity over time if cash burn continues.

Cash Flow

Cash generation is weak, with TTM (Trailing-Twelve-Months) Operating Cash Flow of -$29.8M and Free Cash Flow of -$29.9M, reflecting continued funding needs. Free cash flow declined versus the prior period (TTM free cash flow growth is negative), and cash burn remains elevated relative to the company’s scale. A modest positive is that free cash flow broadly tracks net loss (free cash flow to net income ~1.0), suggesting losses are largely reflected in cash usage rather than being masked by large non-cash adjustments.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	675.00K	951.00K	0.00	0.00
Gross Profit	-273.00K	0.00	675.00K	951.00K	0.00	0.00
EBITDA	-20.68M	-36.23M	-30.18M	-17.89M	-9.38M	0.00
Net Income	-33.41M	-36.73M	-30.54M	-18.06M	-10.02M	-2.51M
Balance Sheet
Total Assets	50.61M	31.67M	14.19M	2.82M	18.74M	204.00K
Cash, Cash Equivalents and Short-Term Investments	42.70M	26.14M	9.70M	455.00K	16.58M	0.00
Total Debt	265.00K	773.00K	811.00K	201.00K	335.00K	2.51M
Total Liabilities	13.13M	24.24M	18.00M	3.28M	2.26M	2.88M
Stockholders Equity	37.48M	7.43M	-3.81M	-466.00K	16.48M	-2.67M
Cash Flow
Free Cash Flow	-29.88M	-28.65M	-18.30M	-15.65M	-5.80M	-1.46M
Operating Cash Flow	-29.83M	-28.57M	-18.28M	-15.65M	-5.77M	-1.46M
Investing Cash Flow	-46.00K	-72.00K	-12.00K	-2.00K	-29.00K	0.00
Financing Cash Flow	40.23M	45.09M	27.54M	-471.00K	22.38M	1.44M

Unicycive Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.92
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UNCY, the sentiment is Positive. The current price of 6.92 is above the 20-day moving average (MA) of 6.51, above the 50-day MA of 6.17, and above the 200-day MA of 5.40, indicating a bullish trend. The MACD of 0.18 indicates Positive momentum. The RSI at 51.43 is Neutral, neither overbought nor oversold. The STOCH value of 54.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UNCY.

Unicycive Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	57 Neutral	$114.24M	-1.56	-49.78%	―	-82.16%	14.58%
FBIO	54 Neutral	$95.60M	-11.51	10.35%	―	-0.32%	94.05%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EQ	50 Neutral	$91.95M	-2.39	-90.24%	―	-90.43%	-382.07%
CBUS	49 Neutral	$155.52M	-0.71	-149.99%	―	-8.64%	85.68%
UNCY	44 Neutral	$139.91M	-2.00	-102.47%	―	―	66.05%
CVM	42 Neutral	$42.13M	-0.65	-176.32%	―	―	48.68%

Unicycive Therapeutics Corporate Events

Unicycive Therapeutics Doubles Stock Sale Agreement

On November 14, 2025, Unicycive Therapeutics, Inc. amended its sales agreement with Guggenheim Securities, LLC to increase the potential sale of its common stock from $50 million to $100 million through an at-the-market offering. This amendment, filed with the U.S. Securities and Exchange Commission, signifies a strategic move to raise additional capital, potentially impacting the company’s financial flexibility and market positioning.

The most recent analyst rating on (UNCY) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Unicycive Therapeutics stock, see the UNCY Stock Forecast page.